pegcetacoplan


( Last Updated : July 28, 2022)
Generic Name:
pegcetacoplan
Project Status:
Pending
Therapeutic Area:
Paroxysmal nocturnal hemoglobinuria
Manufacturer:
SOBI Canada
Call for patient/clinician input open:
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
SR0748-000
Call for patient/clinician input closed:

Details


Manufacturer Requested Reimbursement Criteria1:
Treatment of adult patients with PNH who have an inadequate response to, or are intolerant of, a C5 inhibitor.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
Indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who have an inadequate response to, or are intolerant of, a C5 inhibitor.
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.